Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia

Leukemia

Volumn 26, Issue 5, 2012, Pages 910-917

  McCormack, E ^a,b   Haaland, I ^b   Venas G ^b   Forthun, R B ^b   Huseby, S ^b   Gausdal, G ^b   Knappskog, S ^b   Micklem, D R ^b   Lorens, J B ^b   Bruserud, O ^a,b   Gjertsen, B T ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

acute myeloid leukemia; in vivo imaging; Nutlin 3; p53; valproic acid

Indexed keywords

CD34 ANTIGEN; NUTLIN 3; PROTEIN P53; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER SURVIVAL; CELL DEATH; CONTROLLED STUDY; DRUG POTENTIATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WILD TYPE;

EID: 84860750821     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.315     Document Type: Article

References (38)

1. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487-494.
2. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368: 1894-1907.
3. Laubach J, Rao AV. Current and emerging strategies for the management of acute myeloid leukemia in the elderly. Oncologist 2008; 13: 1097-1108.
4. Wojcik I, Szybka M, Golanska E, Rieske P, Blonski JZ, Robak T et al. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias. Neoplasma 2005; 52: 318-324.
5. Claus R, Lubbert M. Epigenetic targets in hematopoietic malignancies. Oncogene 2003; 22: 6489-6496.
6. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
7. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106: 3150-3159.
8. Gerstner T, Bell N, Konig S. Oral valproic acid for epilepsy-long-term experience in therapy and side effects. Expert Opin Pharmacother 2008; 9: 285-292.
9. Bruserud O, Stapnes C, Ersvaer E, Gjertsen BT, Ryningen A. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr Pharm Biotechnol 2007; 8: 388-400.
10. Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, Bruserud O. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res 2009; 33: 779-787.
11. Bellos F, Mahlknecht U. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologie 2008; 31: 629-633.
12. Quintas-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2011; 25: 226-235.
13. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-5552.
14. Chrisanthar R, Knappskog S, Lokkevik E, Anker G, Ostenstad B, Lundgren S et al. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One 2008; 3: e3062.
15. Wergeland L, Sjoholt G, Haaland I, Hovland R, Bruserud O, Gjertsen BT. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Mol Cancer 2007; 6: 33.
16. Bredholt T, Dimba EA, Hagland HR, Wergeland L, Skavland J, Fossan KO et al. Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. Mol Cancer 2009; 8: 101.
17. Lorens JB, Jang Y, Rossi AB, Payan DG, Bogenberger JM. Optimization of regulated LTR-mediated expression. Virology 2000; 272: 7-15.
18. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-446.
19. Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005; 4: 71-78.
20. Kawagoe R, Kawagoe H, Sano K. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and-independent apoptotic signaling pathways. Leuk Res 2002; 26: 495-502.
21. Bug G, Schwarz K, Schoch C, Kampfmann M, Henschler R, Hoelzer D et al. Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica 2007; 92: 542-545.
22. McCormack E, Micklem DR, Pindard LE, Silden E, Gallant P, Belenkov A et al. In vivo optical imaging of acute myeloid leukemia by green fluorescent protein: time-domain autofluorescence decoupling, fluorophore quantification, and localization. Mol Imaging 2007; 6: 193-204.
23. Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, Appella E et al. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 2008; 68: 3193-3203.
24. Li M, Luo J, Brooks CL, Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 2002; 277: 50607-50611.
25. Palani C, Beck J, Sonnemann J. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. Invest New Drugs 2010; e-pub ahead of print 3 August 2010; doi:10.007/s10637-010-9510-7.
26. Tasdemir E, Chiara Maiuri M, Morselli E, Criollo A, D'Amelio M, Djavaheri-Mergny M et al. A dual role of p53 in the control of autophagy. Autophagy 2008; 4: 810-814.
27. Baehrecke EH. Autophagy: dual roles in life and death? Nat Rev Mol Cell Biol 2005; 6: 505-510.
28. Gu L, Zhu N, Findley HW, Zhou M. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia 2008; 22: 730-739.
29. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. Embo J 2002; 21: 6236-6245.
30. Lau LM, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2008; 27: 997-1003.
31. Blaheta RA, Michaelis M, Natsheh I, Hasenberg C, Weich E, Relja B et al. Valproic acid inhibits adhesion of vincristine-and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer 2007; 96: 1699-1706.
32. Long J, Parkin B, Ouillette P, Bixby D, Shedden K, Erba H et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood 2010; 116: 71-80.
33. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 2006; 281: 33030-33035.
34. Khanim FL, Bradbury CA, Arrazi J, Hayden RE, Rye A, Basu S et al. Elevated FOSBexpression; a potential marker of valproate sensitivity in AML. Br J Haematol 2009; 144: 332-341.
35. McCormack E, Bruserud O, Gjertsen BT. Animal models of acute myelogenous leukaemia-development, application and future perspectives. Leukemia 2005; 19: 687-706.
36. Pearce DJ, Taussig D, Zibara K, Smith LL, Ridler CM, Preudhomme C et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 2006; 107: 1166-1173.
37. Agliano A, Martin-Padura I, Mancuso P, Marighetti P, Rabascio C, Pruneri G et al. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 2008; 123: 2222-2227.
38. Sarek G, Ojala PM. p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo: new hope for treating aggressive viral lymphomas. Cell Cycle 2007; 6: 2205-2209.